Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Clinical Update - Debio 9902 SR in Alzheimer's Disease
March 21st, 2008
Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced that following a meeting of the independent Data Safety Monitoring Board (DSMB), the Company received a recommendation to continue its Phase II BRAINz study with Debio 9902 SR (sustained release) for the treatment of Alzheimer's disease (AD),without modification. The DSMB's objective is to monitor the well being and safety of patients participating in a study and to review the safety data throughout its duration. "This recommendation by the DSMB authorising Debiopharm to continue the...
Source: Health Business Week (2008-03-21)
|
